Thiopurine methyltransferase genotype and the toxicity of azathioprine in Japanese

被引:45
作者
Ishioka, S [1 ]
Hiyama, K [1 ]
Sato, H [1 ]
Yamanishi, Y [1 ]
McLeod, HL [1 ]
Kumagai, K [1 ]
Maeda, H [1 ]
Yamakido, M [1 ]
机构
[1] Hiroshima Univ, Sch Med, Dept Internal Med 2, Minami Ku, Hiroshima 7348551, Japan
关键词
allele; bone marrow toxicity; rheumatic disease;
D O I
10.2169/internalmedicine.38.944
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
Objective Thiopurine S-methyltransferase (TPMT) is a cytosolic enzyme that preferentially catalyzes the S-methylation of aromatic and heterocyclic sulfhydryl compounds, including Azathioprine (AZA), It has been reported that the level of AZA toxicity is dependent on the TPMT genotypes in Caucasian individuals; we thus investigated this relationship in Japanese. Methods The TPMT genotype was determined using peripheral blood cell DNA obtained from 36 Japanese patients with rheumatic diseases who were treated with AZA, by polymerase chain reaction (PCR) technique. Duration of AZA administration, white blood cell counts before and after AZA administration, and side effects were investigated in each subject, and were compared between the patients with or without TPMT mutation. Results The TPMT allelotype was TPMT*1/TPMT*1 in 33 (91.7%) and TPMT*1/TPMT*3C in 3 (8.3%) individuals, All 3 patients (100%) with the mutant TPMT allele (TPMT*3C) discontinued AZA treatment due to leucopenia while only 4 patients (12%) without mutant TPMT alleles showed leucopenia (p = 0.0049, Fisher's exact test), However, leucopenia developed relatively late in patients with mutant TPMT. Conclusion The TPMT mutant allele, TPMT*3C, also exists in Japanese individuals, and the bone marrow toxicity of AZA is likely stronger in patients with this mutant allele.
引用
收藏
页码:944 / 947
页数:4
相关论文
共 14 条
[1]   Thiopurine methyltransferase alleles in British and Ghanaian populations [J].
Ameyaw, MM ;
Collie-Duguid, ESR ;
Powrie, RH ;
Ofori-Adjei, D ;
McLeod, HL .
HUMAN MOLECULAR GENETICS, 1999, 8 (02) :367-370
[2]   Thiopurine methyltransferase genotype predicts therapy-limiting severe toxicity from azathioprine [J].
Black, AJ ;
McLeod, HL ;
Capell, HA ;
Powrie, RH ;
Matowe, LK ;
Pritchard, SC ;
Collie-Duguid, ESR ;
Reid, DM .
ANNALS OF INTERNAL MEDICINE, 1998, 129 (09) :716-718
[3]   The frequency and distribution of thiopurine methyltransferase alleles in Caucasian and Asian populations [J].
Collie-Duguid, ESR ;
Pritchard, SC ;
Powrie, RH ;
Sludden, J ;
Collier, DA ;
Li, T ;
McLeod, HL .
PHARMACOGENETICS, 1999, 9 (01) :37-42
[4]   Genetic polymorphism of thiopurine S-methyltransferase: Clinical importance and molecular mechanisms [J].
Krynetski, EY ;
Tai, HL ;
Yates, CR ;
Fessing, MY ;
Loennechen, T ;
Schuetz, JD ;
Relling, MV ;
Evans, WE .
PHARMACOGENETICS, 1996, 6 (04) :279-290
[5]   A SINGLE-POINT MUTATION LEADING TO LOSS OF CATALYTIC ACTIVITY IN HUMAN THIOPURINE S-METHYLTRANSFERASE [J].
KRYNETSKI, EY ;
SCHUETZ, JD ;
GALPIN, AJ ;
PUI, CH ;
RELLING, MV ;
EVANS, WE .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 1995, 92 (04) :949-953
[6]   Isolation of a human thiopurine S-methyltransferase (TPMT) complementary DNA with a single nucleotide transition A719G (TPMT*3C) and its association with loss of TPMT protein and catalytic activity in humans [J].
Loennechen, T ;
Yates, CR ;
Fessing, MY ;
Relling, MV ;
Krynetski, EY ;
Evans, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1998, 64 (01) :46-51
[7]   THIOPURINE METHYLTRANSFERASE ACTIVITY IN AMERICAN WHITE SUBJECTS AND BLACK SUBJECTS [J].
MCLEOD, HL ;
LIN, JS ;
SCOTT, EP ;
PUI, CH ;
EVANS, WE .
CLINICAL PHARMACOLOGY & THERAPEUTICS, 1994, 55 (01) :15-20
[8]  
Stolk JN, 1998, ARTHRITIS RHEUM-US, V41, P1858, DOI 10.1002/1529-0131(199810)41:10<1858::AID-ART19>3.3.CO
[9]  
2-#
[10]   Thiopurine methyltransferase pharmacogenetics: Human gene cloning and characterization of a common polymorphism [J].
Szumlanski, C ;
Otterness, D ;
Her, C ;
Lee, D ;
Brandriff, B ;
Kelsell, D ;
Spurr, N ;
Lennard, L ;
Wieben, E ;
Weinshilboum, R .
DNA AND CELL BIOLOGY, 1996, 15 (01) :17-30